Precision Engineering Defines Next-Gen ADC

Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC Conference, leaders across discovery, development, and manufacturing highlighted the accelerating momentum of this clinically maturing field.

The post Precision Engineering Defines Next-Gen ADC appeared first on GEN - Genetic Engineering and Biotechnology News.